Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
China Shineway Pharmaceutical Holdings Limited, commonly referred to as Shineway, is a prominent player in the pharmaceutical preparation manufacturing industry. Headquartered in China (CN), the company has established a significant presence across various operational regions, focusing on the development and production of high-quality pharmaceutical products.
Founded in 1992, Shineway has achieved notable milestones, including the expansion of its product portfolio and enhancements in manufacturing capabilities. The company is renowned for its core offerings, which include traditional Chinese medicine and modern pharmaceuticals, distinguished by their efficacy and adherence to stringent quality standards.
With a strong market position, Shineway has garnered recognition for its commitment to innovation and excellence, making it a trusted name in the pharmaceutical sector. Its dedication to research and development further solidifies its reputation as a leader in the industry.
-22 vs industry average
China Shineway Pharmaceutical’s score of 20 is lower than 21% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing is among the most carbon-intensive industries
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
China Shineway Pharmaceutical, a Pharmaceutical Preparation Manufacturing company headquartered in CN, has reported its carbon emissions, with the most recent comprehensive data available for 2021.
In 2021, China Shineway Pharmaceutical's total greenhouse gas emissions were 117,794,000 kg CO2e. This included Scope 1 emissions of 76,087,000 kg CO2e, Scope 2 emissions of 16,885,000 kg CO2e, and Scope 3 emissions of 24,822,000 kg CO2e.
Looking back, the company's total emissions were higher in previous years: 130,989,000 kg CO2e in 2020, 145,136,000 kg CO2e in 2019, 145,465,000 kg CO2e in 2018, and 153,410,000 kg CO2e in 2017.
While no absolute emissions data is available for 2024, 2023, and 2022, the company has provided emission factors. For 2024, the GHG intensity per assets was 9.48e-06 per RMB, and the Scope 3 GHG per employee was 6,330 kg CO2e. In 2023, the GHG intensity per EBITDA was 0.09882 per CNY. For 2022, the GHG intensity per sales was 3.579e-05 per RMB, and the GHG intensity per employee was 34,220 kg CO2e.
China Shineway Pharmaceutical's emissions data is cascaded from its parent company, China Shineway Pharmaceutical Group Limited. The company has not publicly disclosed any specific reduction targets or climate pledges, nor has it set any Science Based Targets (SBTi).
No climate goals have been disclosed for China Shineway Pharmaceutical yet.
No scope 3 category breakdown has been disclosed yet.


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more